Literature DB >> 12043384

Probiotics in clinical conditions.

Philippe R Marteau1.   

Abstract

Probiotics are nonpathogenic microorganisms which, when ingested, exert a positive influence on the health or physiology of the host. Their mechanisms of action and effects are now studied using the same pharmacological approach as for drugs. This article summarizes and comments on evidence for the positive effects of probiotics in various clinical situations. Substantial evidence can be achieved when randomized controlled trials or meta-analyses show positive results. The clinical situations studied include prevention or treatment of antibiotic-associated disorders, gastroenteritis, and diarrhea, lactose intolerance, intestinal infections and colonization by pathogenic bacteria (including Helicobacter pylori and Clostridium difficile), traveler's diarrhea, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colonic cancer, urogenital infections and tumors, allergy (especially atopic eczema), vaccination, and cholesterol lowering. Current probiotics have an excellent safety record--another topic discussed in this article.

Entities:  

Mesh:

Year:  2002        PMID: 12043384     DOI: 10.1007/s12016-002-0011-0

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  84 in total

Review 1.  Consumption of fermented and nonfermented dairy products: effects on cholesterol concentrations and metabolism.

Authors:  M P St-Onge; E R Farnworth; P J Jones
Journal:  Am J Clin Nutr       Date:  2000-03       Impact factor: 7.045

2.  Efficacy of Lactobacillus GG as a Diarrheal Preventive in Travelers.

Authors: 
Journal:  J Travel Med       Date:  1997-03-01       Impact factor: 8.490

3.  Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.

Authors:  A Attar; B Flourié; J C Rambaud; C Franchisseur; P Ruszniewski; Y Bouhnik
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

4.  A double-blind comparison of two different treatments for acute enteritis in adults.

Authors:  E Camarri; A Belvisi; G Guidoni; G Marini; G Frigerio
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

Review 5.  Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics.

Authors:  F Shanahan
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

6.  [Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study].

Authors:  H Kollaritsch; H Holst; P Grobara; G Wiedermann
Journal:  Fortschr Med       Date:  1993-03-30

7.  Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB.

Authors:  M H Coconnier; V Lievin; E Hemery; A L Servin
Journal:  Appl Environ Microbiol       Date:  1998-11       Impact factor: 4.792

8.  Treatment of bacterial vaginosis with lactobacilli.

Authors:  A Hallén; C Jarstrand; C Påhlson
Journal:  Sex Transm Dis       Date:  1992 May-Jun       Impact factor: 2.830

9.  Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study.

Authors:  K Plein; J Hotz
Journal:  Z Gastroenterol       Date:  1993-02       Impact factor: 2.000

10.  Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea.

Authors:  A Guarino; R B Canani; M I Spagnuolo; F Albano; L Di Benedetto
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-11       Impact factor: 2.839

View more
  16 in total

Review 1.  Probiotics and prebiotics in the elderly.

Authors:  J M T Hamilton-Miller
Journal:  Postgrad Med J       Date:  2004-08       Impact factor: 2.401

2.  Bifidobacterium bifidum in probiotic Edam cheese: influence on cheese ripening.

Authors:  Latha Sabikhi; M H Sathish Kumar; B N Mathur
Journal:  J Food Sci Technol       Date:  2013-02-10       Impact factor: 2.701

3.  Flow cytometric testing of green fluorescent protein-tagged Lactobacillus rhamnosus GG for response to defensins.

Authors:  Sigrid C J De Keersmaecker; Kristien Braeken; Tine L A Verhoeven; Mónica Perea Vélez; Sarah Lebeer; Jos Vanderleyden; Pascal Hols
Journal:  Appl Environ Microbiol       Date:  2006-07       Impact factor: 4.792

Review 4.  Functional foods-based diet as a novel dietary approach for management of type 2 diabetes and its complications: A review.

Authors:  Parvin Mirmiran; Zahra Bahadoran; Fereidoun Azizi
Journal:  World J Diabetes       Date:  2014-06-15

Review 5.  Potential uses of probiotics in clinical practice.

Authors:  Gregor Reid; Jana Jass; M Tom Sebulsky; John K McCormick
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

6.  Infant intestinal Enterococcus faecalis down-regulates inflammatory responses in human intestinal cell lines.

Authors:  Shugui Wang; Lydia Hui Mei Ng; Wai Ling Chow; Yuan Kun Lee
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

7.  The Efficacy of Probiotic (Lactobacillus rhamnosus GG) and 5-ASA (Aminosalicylic Acid) in the Treatment of Experimental Radiation Proctitis in Rats.

Authors:  Özgür Dandin; Mehmet Levhi Akin; Ahmet Ziya Balta; Ergün Yücel; Dursun Özgür Karakaş; Sezai Demirbaş; Sevim Özdemir; Apdullah Haholu
Journal:  Indian J Surg       Date:  2013-05-05       Impact factor: 0.656

Review 8.  Non-pulmonary allergic diseases and inflammatory bowel disease: a qualitative review.

Authors:  David S Kotlyar; Mili Shum; Jennifer Hsieh; Wojciech Blonski; David A Greenwald
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

9.  Probiotics and allergy: Current understanding and application for the PCCP (Primary Care Chiropractic Physician).

Authors:  Christopher S Chalk; Alan J Chalk
Journal:  J Chiropr Med       Date:  2003

10.  Efficacy of oral fecal bacteriotherapy in rhesus macaques (Macaca mulatta) with chronic diarrhea.

Authors:  Christie E Ferrecchia; Theodore R Hobbs
Journal:  Comp Med       Date:  2013-02       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.